Swiss Hypertension and Risk Factor Program (SHARP): Cardiovascular risk factors management in patients with type 2 diabetes in Switzerland

Figures & data

Figure 1 Estimate of hypertensive patients (upper panel) and hypertensive diabetics (lower panel) attaining their target blood pressure values as predicted by their doctors in I‐SHARP (solid bars), proportion of hypertensive patients actually achieving measured target goals in SHARP (open bars), and proportion of patients attaining blood pressure values <135/85 mmHg as recommended by the Swiss Society of Hypertension, SSH (gray bars).

Table I. I‐SHARP: Physicians testing for risk factors (answers “yes” and “most of the time”).

Initial diagnosis, with cardiovascular risk factor	General practitioners	Specialists	Total
n	688	352	1040
Hypertension
Microalbuminuria/proteinuria	48%	52%	49%
Dyslipidemia	96%	96%	96%
Hypertension+diabetes mellitus
Microalbuminuria/proteinuria	86%	89%	87%
Dyslipidemia	97%	98%	98%

Figure 2 Distribution of diabetes, hypertension and dyslipidemia among the 20,956 patients censored in the SHARP cohort.

Figure 3 Prevalence of diabetes mellitus alone (open bars), hypertension alone (gray bars), and diabetes with hypertension (solid bars) in different age groups (entire patient population, n=20,956).

Table II. Prevalence of hypertension, diabetes and other cardiovascular risk factors in the SHARP cohort.

	Patients with condition	Estimated prevalence
Condition
Hypertension	6211 (3127 unknown)	30–35%
Diabetes type 2	2145 (5305 unknown)	10–14%
Dyslipidemia	4100 (7638 unknown)	20–31%
Microalbuminuria/proteinuria	917 (11880 unknown)	4–10%
Hypertension and diabetes	1431 (5383 unknown)	7–9%
Subpopulation: known hypertensive patients (6211)
Additional condition
Diabetes	1431 (366 unknown)	23–24%
Dyslipidemia	2334 (1000 unknown)	38–45%
Microalbuminuria/proteinuria	643 (2811 unknown)	10–19%
Subpopulation: known diabetic patients (2145)
Additional condition
Hypertension	1431 (58 unknown)	67–69%
Dyslipidemia	974 (241 unknown)	45–51%
Microalbuminuria/proteinuria	583 (639 unknown)	27–39%
Subpopulation: known hypertensive diabetic patients (1431)
Additional condition
Microalbuminuria/proteinuria	427 (415 unknown)	30–42%
Dyslipidemia	718 (151 unknown)	50–56%

Table III. Prevalence of pharmacological treatment of hypertension, diabetes and dyslipidemia in the SHARP cohort.

Condition	Patients treated	Estimated rate
Hypertension	5692 (128 unknown)	92–94%
Diabetes type 2	1663 (54 unknown)	78–80%
Dyslipidemia	2256 (73 unknown)	55–56%